C3orf22: A Potential Drug Target and Biomarker for Chromosome 3 Open Reading Frame 22

Target Name: C3orf22

NCBI ID: G152065

C3orf22

Other Name(s): Chromosome 3 open reading frame 22, transcript variant 1 | Uncharacterized protein C3orf22 | chromosome 3 open reading frame 22 | CC022_HUMAN | C3orf22 variant 1

C3orf22: A Potential Drug Target and Biomarker for Chromosome 3 Open Reading Frame 22

Chromosome 3 (3p) is one of the chromosomes that contribute to the genetic diversity of humans. It is home to numerous genes, including the open reading frame (ORF) 22 gene, which encodes a protein involved in various cellular processes. However, individuals with genetic disorders caused by mutations in the 3p ORF22 gene have limited understanding of the underlying mechanisms. C3orf22, a splice variants of ORF22, has been identified as a potential drug target and biomarker for these disorders. This article will discuss the ORF22 gene, its splice variants, and the potential implications for C3orf22 as a drug target and biomarker.

ORF22 gene and its splice variants

The ORF22 gene is located on chromosome 3 at position 116.7 kb (KMN176.4). It encodes a protein named Myotonic Dystrophy Containing 22 (MDC22), which is involved in muscle strength and function. The ORF22 gene has four splice variants, designated as ORF22-1, ORF22-2, ORF22-3, and ORF22-4. These variants differ in the last exon, resulting in different protein sizes and functions.

ORF22-1 is the most abundant splice variant, accounting for approximately 95% of the ORF22 gene transcripts. It is a 21-kb protein that contains 115 amino acids and has a calculated pI of 1.88. ORF22-1 is expressed in various tissues, including muscle, heart, brain, and peripheral blood. It is involved in the regulation of muscle strength and function, suggesting a potential role in muscle-related diseases.

ORF22-2 is a less abundant splice variant, accounting for approximately 5% of the ORF22 gene transcripts. It is a 13.5-kb protein that contains 95 amino acids and has a calculated pI of 2.01. ORF22-2 is expressed in muscle and heart. Its function is similar to that of ORF22-1, but with a smaller molecular size.

ORF22-3 and ORF22-4 are the least abundant splice variants, accounting for approximately 1% of the ORF22 gene transcripts. ORF22-3 is a 6.8-kb protein that contains 71 amino acids and has a calculated pI of 2.19, while ORF22-4 is a 1.9-kb protein that contains 72 amino acids and has a calculated pI of 2.35. Both ORF22-3 and ORF22-4 are expressed in various tissues, including muscle, heart, and brain.

Potential implications of C3orf22 as a drug target

C3orf22 has been identified as a potential drug target due to its involvement in various cellular processes that are affected in various diseases. The dysfunction of the ORF22 gene has been implicated in various muscle-related disorders, such as myotonic dystrophy, a genetic disorder characterized by muscle stiffness and progressive muscle weakness. Additionally, altered ORF22 expression has been observed in various diseases, including neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

C3orf22 has also been shown to play a role in cancer progression, as increased ORF22 expression has been observed in various cancer types. Therefore, targeting the ORF22 gene has the potential to develop new treatments for various diseases.

Biomarker potential of C3orf22

C3orf22 has also been identified as a potential biomarker for various diseases. Its expression is known to be affected by various factors, including age, gender, and disease status. For instance, higher ORF22 expression has been observed in individuals with certain diseases, such as heart disease and diabetes. Additionally, altered ORF22 expression has

Protein Name: Chromosome 3 Open Reading Frame 22

The "C3orf22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C3orf22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets